(Q44120885)

30 November 2017

Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients (English)

1 reference

30 November 2017

0 references

1 reference

coronary artery disease

1 reference

6

Ernst J Schaefer

1 reference

30 November 2017

Bela F Asztalos

1

1 reference

30 November 2017

Katalin V Horvath

2

1 reference

30 November 2017

Judith R McNamara

3

1 reference

30 November 2017

Paul S Roheim

4

1 reference

30 November 2017

Joel J Rubinstein

5

1 reference

30 November 2017

1 October 2002

1 reference

30 November 2017

1 reference

30 November 2017

164

1 reference

30 November 2017

2

1 reference

30 November 2017

361-369

1 reference

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

30 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

What targets should lipid-modulating therapy achieve to optimise the prevention of coronary heart disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Cholesterol reduction yields clinical benefit: impact of statin trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Triglycerides and atherogenic lipoproteins: rationale for lipid management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Prevention of coronary heart disease by raising high-density lipoprotein cholesterol?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Normolipidemic subjects with low HDL cholesterol levels have altered HDL subpopulations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Lowering effects of four different statins on serum triglyceride level

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients witb hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900149-1

10.1016/S0021-9150(02)00149-1

7 January 2021

Identifiers

DOI

1 reference

release_3hovc2uchrbldgaera4rnhyp7i

30 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3hovc2uchrbldgaera4rnhyp7i

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference